Immunotherapy Drug Shows Promise for Metastatic Merkel Cell Carcinoma

By Jim Stallard,

Dermatologist examining skin on the face of older man.
Summary

Merkel cell carcinoma is hard to treat after it has spread. A new immunotherapy drug, avelumab, was recently approved by the FDA for people with metastatic Merkel cell carcinoma who had previously received chemotherapy. Now new research suggests avelumab could be even more effective if given as an initial treatment in these patients.

Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer, is highly treatable if caught early. For people whose disease has metastasized, or spread, it’s a different story. Tumors often respond to chemotherapy by shrinking, but only for a short time before they start growing again.

Recently, new hope has emerged for people with metastatic MCC. In March 2017, the US Food and Drug Administration approved the immunotherapy drug avelumab (Bavencio®) for people with metastatic disease who had previously received chemotherapy. It was the first FDA-approved drug for metastatic MCC. The approval came after an international phase II clinical trial showed that about one-third of people responded to avelumab. Unlike with chemotherapy, the benefit appears to be lasting.

A second stage of the clinical trial has now found that avelumab might be even more effective as an initial treatment. Results reported in JAMA Oncology show that 62% of people with metastatic MCC who received avelumab as their first treatment had their tumors shrink.

“This is important progress in managing this cancer, which hasn’t had a good treatment option for the advanced stage,” says Memorial Sloan Kettering medical oncologist Sandra D’Angelo. She is a corresponding author of the JAMA Oncology study and led the MSK portion of the multisite trial.

An Immune Component

Merkel cells are located in the outermost layer of the skin and are mainly touch receptors. Merkel cell tumors typically begin on sun-exposed parts of the body, such as the face and neck. Their shape and color are less distinctive than other skin cancers, so people usually only notice them because of rapid growth. The disease is diagnosed in just 1,500 people each year in the United States, and in about 10% of those people, it has already spread.

This is important progress in managing this cancer, which hasn't had a good treatment option for the advanced stage.
Sandra P. D'Angelo
Sandra P. D'Angelo medical oncologist

Despite its rarity, MCC has been well studied. Researchers suspect that some loss of immune function plays a critical role in triggering the cancer. About 80% of people with the disease have a virus called Merkel cell polyomavirus, and MCC is more likely to develop in people with a weakened immune system.

“Like with most cancers, we think it’s not just one factor alone that causes the disease. It’s due to multiple hits,” Dr. D’Angelo says. “Someone may get the virus, then they get older and their immune system weakens, or they have sun exposure over the years that causes further DNA damage, and normal Merkel cells become cancerous.”

Evidence of an immune component in MCC prompted researchers and pharmaceutical companies to test avelumab for the disease. Avelumab is a type of drug called a checkpoint inhibitor. It targets a molecule called PD-L1, which is part of the surface of some cancer cells and immune cells and prevents the immune system from recognizing that the cancer cells pose a threat. By binding to PD-L1, avelumab takes the brakes off the immune system and allows it to attack the cancer.

Avelumab was already being tested in a variety of cancers, including melanoma, gastric (stomach) cancer, lung cancer, and ovarian cancer. Merck KGaA and Pfizer funded a large trial to test its effectiveness in people with metastatic MCC.

Back to top Arrow (up) icon.Icon pointing upwards. Usually means that the containing element can be opened and closed.

More Effective as Initial Treatment for MCC

The first part of the phase II trial, which led to the FDA approval, involved only people with metastatic MCC who had not responded to chemotherapy. The response rate in this group was approximately 33%. The FDA requested a second part to the trial, which Dr. D’Angelo led, to look at avelumab strictly as an initial therapy in an additional 112 people.

Early results from the first 39 people in the second part of the trial were striking. The response rate to avelumab, 62%, was almost double the response rate in the original group. This suggested that avelumab might be much more effective if given as an initial treatment.

Dr. D’Angelo adds that further research will study ways to identify who is more likely to benefit from avelumab to start. “We’re still helping only about 60% of people with disease that has spread, which highlights a need for us to understand more about it,” she explains.

Researchers also will explore combining avelumab with other immunotherapy drugs. This strategy has been effective against other cancers, especially melanoma.

Back to top Arrow (up) icon.Icon pointing upwards. Usually means that the containing element can be opened and closed.

Expanding Research Efforts to Earlier-Stage MCC

In addition, a new clinical trial is about to start that will test whether avelumab can help those with MCC at an earlier stage. People who have had MCC surgically removed but are at a high risk of the disease coming back may be able to reduce their risk with avelumab. MSK is participating in this trial under the direction of medical oncologist Ciara Kelly.

“This has been such an encouraging development for this disease,” Dr. D’Angelo says. “When I first started treating people with Merkel cell carcinoma at MSK, the only thing I had to offer them was chemotherapy, and I knew how limited the benefit would be. It is great to have this therapy that’s available to block tumor growth and potentially allow people to live longer.”

Back to top Arrow (up) icon.Icon pointing upwards. Usually means that the containing element can be opened and closed.

Comments

My son is 43 years old . He has Merkel câncer . PleDe provide me with information

Dear Donata, we're sorry to hear about your son's diagnosis. If you would like to learn more about Merkel cell cancer, you can go to: https://www.mskcc.org/cancer-care/types/merkel-cell-carcinoma

If your son would like to come to MSK for a consultation, he can call 800-525-2225 or go to https://www.mskcc.org/experience/become-patient/appointment for more information on making an appointment.

Thank you for your comment and best wishes to you and your family.

Is this drug Avelumab used for immunotheraphy in Australia for MCC?..how often is it administered..and is it used with chemotherapy at same time. ?

My 95 year old mother in law was diagnosed with Merkel cell carcinoma. They have done a PET scan but are still waiting for results. It was caught thru normal dermatologist skin check and was a very small speck on her nose. At this age, (she is a healthy 95 year old still driving and living with husband), what can be expected? Should her doctor want to do more than remove it at this age? She is at peace with this diagnosis, but also just doing what is told she should do without questioning anything! We do not want her quality of life she has now to change. It seems that her age must be taken into consideration as to her treatment. She has mentioned radiation after the exercising, but is this safe for a 95 year old?

Dear Kay, we're very sorry to hear about your mother's diagnosis. If she would like to come to MSK for a consultation and to learn about her treatment options, the number to call is 800-525-2225. You can go to https://www.mskcc.org/experience/become-patient/appointment for more information on making an appointment. Thank you for your comment, and best wishes to you and your family.

Add new comment

We welcome your questions and comments. While we share many of them with our world-class doctors and researchers, we regret that in order to protect your privacy, we are not able to make personal medical recommendations on this forum, nor do we publish comments that contain your personal information. If you would like to consult with an MSK doctor, we encourage you to make an appointment at 800-525-2225 or request an appointment online.

Your email address is kept private and will not be shown publicly.